Revenue Performance - Q1 2025 net product revenue for ZORYVE was $63.8 million, a 196% increase compared to Q1 2024, but a 2% decrease from Q4 2024[4] - Total revenues for Q1 2025 reached $65.846 million, a 32.7% increase from $49.569 million in Q1 2024[26] - Product revenue, net, significantly increased to $63.846 million from $21.569 million, marking a 196.5% growth year-over-year[26] Expenses - Selling, general, and administrative expenses for Q1 2025 were $64.0 million, up from $54.8 million in Q1 2024, primarily due to increased compensation and personnel-related expenses[15] - Operating expenses totaled $90.375 million, up from $81.191 million, reflecting an increase of 11.5%[26] - Research and development expenses decreased to $17.5 million in Q1 2025 from $23.1 million in Q1 2024, attributed to reduced clinical development costs[14] - Research and development expenses decreased to $17.543 million from $23.141 million, a reduction of 24.2%[26] - Other income, net, was $2.730 million, down from $4.044 million, a decrease of 32.4%[26] - Interest expense decreased significantly to $(2.982) million from $(7.480) million, a reduction of 60.1%[26] Net Loss - The company reported a net loss of $25.1 million, or $0.20 per share, for Q1 2025, compared to a net loss of $35.4 million, or $0.32 per share, for Q1 2024[16] - The net loss for Q1 2025 was $25.060 million, an improvement compared to a net loss of $35.382 million in Q1 2024, representing a 29.2% reduction[26] - Net loss per share improved to $(0.20) from $(0.32) year-over-year[26] Product Demand and Development - Demand for ZORYVE cream 0.3% in plaque psoriasis grew with over 425,000 prescriptions filled since launch, reflecting high patient and physician satisfaction[8] - ZORYVE cream 0.15% for atopic dermatitis has filled over 69,000 prescriptions since launch, with coverage by the three largest national Pharmacy Benefit Managers[8] - The company submitted a supplemental New Drug Application for ZORYVE cream 0.05% for treating atopic dermatitis in children ages 2 to 5, with a PDUFA action date of October 13, 2025[8] - The company has a PDUFA action date of May 22, 2025, for ZORYVE foam 0.3% for treating plaque psoriasis of the scalp and body[4] Legal Matters - The patent litigation against Padagis was stayed, with the court cancelling all case deadlines, including the trial[4] Cash Position - Cash, cash equivalents, and marketable securities totaled $198.7 million as of March 31, 2025, down from $228.6 million at the end of 2024[16] Share Information - The weighted-average shares used in computing net loss per share increased to 126,036,862 from 111,048,525, an increase of 13.5%[26]

Core Insights - Arcutis Biotherapeutics reported strong financial performance in Q1 2025, driven by significant demand growth for its ZORYVE portfolio, which offers a safe alternative to steroids [2][6][10] - The company is expanding its market presence with additional indications and coverage for ZORYVE, alongside a promising pipeline of products [2][6][8] Financial Performance - Q1 2025 net product revenue for ZORYVE reached $63.8 million, marking a 196% increase compared to Q1 2024, but a 2% decrease from Q4 2024 [6][10] - Total revenues for Q1 2025 were $65.8 million, compared to $49.6 million in Q1 2024 [10][24] - The net loss for Q1 2025 was $25.1 million, or $0.20 per share, an improvement from a net loss of $35.4 million, or $0.32 per share, in Q1 2024 [14][24] Product Updates - ZORYVE cream and foam are approved for treating various skin conditions, with ZORYVE cream 0.3% being the most prescribed non-steroidal topical treatment for plaque psoriasis and atopic dermatitis [3][4][7] - The company has submitted supplemental New Drug Applications (sNDAs) for ZORYVE cream 0.05% for children and ZORYVE foam for scalp and body psoriasis, with action dates set for October 13, 2025, and May 22, 2025, respectively [7][10] Market Expansion - Over 425,000 prescriptions for ZORYVE cream 0.3% have been filled since its launch, indicating strong physician and patient satisfaction [7] - The company is expanding Medicaid coverage, with over 50% of recipients now covered, and all three largest national Pharmacy Benefit Managers (PBMs) covering the entire ZORYVE portfolio [2][6] Research and Development - Arcutis is advancing its pipeline, including ARQ-255 for alopecia areata, with data expected in mid-2025 [8] - The company is also developing ARQ-234, a potential biologic treatment for atopic dermatitis, with plans to submit an Investigational New Drug application in 2025 [8] Corporate Developments - Latha Vairavan was appointed as Chief Financial Officer effective May 6, 2025 [15] - The company obtained two new U.S. patents related to topical roflumilast compositions in Q1 2025 [15]

Wall Street expects a year-over-year increase in earnings on higher revenues when Arcutis Biotherapeutics, Inc. (ARQT) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 6, 2025, might help the stock move higher if these key numbers are be ...

Core Insights - The article discusses potential investment opportunities in ARQT, indicating a possible long position in the stock within the next 72 hours [1]. Group 1 - The analyst has no current stock or derivative positions in the companies mentioned but may initiate a beneficial long position [1]. - The article expresses the author's own opinions and is not influenced by compensation from any company [1]. - There is no business relationship with any company whose stock is mentioned in the article [1].

Core Viewpoint - Arcutis Biotherapeutics, Inc. will report its first quarter 2025 financial results and provide a business update on May 6, 2025, after U.S. financial markets close [1] Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on innovations in immuno-dermatology, addressing the needs of individuals with immune-mediated dermatological diseases [3] - The company has a growing portfolio that includes three FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [3] Upcoming Events - A conference call and webcast will be held on May 6, 2025, at 4:30 p.m. ET, with a live webcast available on the company's website [2]

Core Insights - Arcutis Biotherapeutics announces the retirement of CFO David Topper and the appointment of Latha Vairavan as the new CFO, effective May 15, 2025, as part of a planned succession [1][3][5] Company Leadership Transition - David Topper has served as CFO since April 2024, playing a crucial role in strengthening Arcutis' financial position, including renegotiating debt and enhancing investor relations [2][3] - Latha Vairavan, with over 20 years of finance experience in the biotech industry, will succeed Topper, bringing a deep understanding of the business and strong industry relationships [4][5] Financial Position and Growth Strategy - Under Topper's leadership, Arcutis has positioned itself for future growth, with a focus on the commercialization of its product ZORYVE [2][3][5] - Vairavan expressed excitement about her new role, emphasizing the company's momentum and commitment to further commercializing ZORYVE for various inflammatory skin conditions [5] Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a growing portfolio that includes three FDA-approved products [5]

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) shares experienced a significant increase of 10.8% to close at $16.60, driven by strong trading volume and positive developments in patent litigation [1][2]. Company Summary - The stock's recent rally was influenced by Padagis requesting a stay in the ongoing patent litigation concerning Arcutis' Zoryve (roflumilast) cream 0.3%, which is used for treating plaque psoriasis [2]. - Arcutis is projected to report a quarterly loss of $0.17 per share, reflecting a year-over-year increase of 46.9%, with expected revenues of $63.95 million, marking a 29% rise from the previous year [2]. - The consensus EPS estimate for Arcutis has remained stable over the last 30 days, indicating that the stock's price movement may not sustain without changes in earnings estimate revisions [4]. Industry Summary - Arcutis operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Codexis (CDXS), saw a decline of 0.8% to $2.49 and has returned -6.3% over the past month [4]. - Codexis has experienced a 4.4% increase in its consensus EPS estimate for the upcoming report, now at -$0.20, which is a 25% decrease from the previous year's report [5].

Core Viewpoint - Arcutis Biotherapeutics has agreed to a joint stipulation to stay ongoing patent litigation with Padagis, preserving its intellectual property rights and the Hatch-Waxman stay for its product ZORYVE [1][2][3] Group 1: Patent Litigation and Agreement - Padagis has requested a stay in the patent litigation against Arcutis, which the company has agreed to, leading to the vacating of all trial dates [1] - The joint stipulation requires Padagis to inform Arcutis of any FDA correspondence regarding their ANDA for a generic version of ZORYVE [2] - The Hatch-Waxman stay of regulatory approval will be extended by one day for each day the litigation is stayed, ensuring Arcutis retains its benefits under the Act [2] Group 2: Product Information and Market Position - ZORYVE cream 0.3% is indicated for the treatment of plaque psoriasis in patients aged 6 and older, with patent protection extending until at least 2037 [3][5] - The company aims to enhance the adoption of ZORYVE as a safe alternative to steroids for treating inflammatory dermatoses [3] - Arcutis has a growing portfolio of FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions [4]

Group 1 - Arcutis Biotherapeutics, Inc. (ARQT) shares have increased by 25.7% over the past four weeks, closing at $16.09, with a mean price target of $20.25 indicating a potential upside of 25.9% [1] - The average price targets from analysts range from a low of $15 to a high of $29, with a standard deviation of $3.96, suggesting variability in estimates [2] - Analysts show a consensus that ARQT will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][10] Group 2 - The Zacks Consensus Estimate for ARQT has increased by 50.7% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [11] - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [12]

Core Insights - Arcutis Biotherapeutics, Inc. will participate in the 24th Annual Needham Virtual Healthcare Conference from April 7–10, 2025, with a fireside chat scheduled for April 8, 2025, at 11:00 am EDT [1] - The company focuses on developing innovations in immuno-dermatology, addressing the needs of patients with immune-mediated dermatological diseases [2] Company Overview - Arcutis is a commercial-stage medical dermatology company with a commitment to addressing persistent patient challenges in dermatology [2] - The company has a growing portfolio that includes three FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [2]